Related references
Note: Only part of the references are listed.VLA-4 and CXCR4 expression levels show contrasting prognostic impact (favorable and unfavorable, respectively) in acute myeloid leukemia
Mi Hyun Bae et al.
ANNALS OF HEMATOLOGY (2015)
Antileukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapy
Byung-Sik Cho et al.
BLOOD (2015)
Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia
C. Michel Zwaan et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Adverse prognostic impact of KIT mutations in childhood CBF-AML: the results of the Japanese Pediatric Leukemia/Lymphoma Study Group AML-05 trial
M. Tokumasu et al.
LEUKEMIA (2015)
Mobilisation of haematopoietic stem cells in paediatric patients, prior to autologous transplantation following administration of plerixafor and G-CSF
Bhumik Patel et al.
PEDIATRIC BLOOD & CANCER (2015)
CXCR4 Expression Accounts for Clinical Phenotype and Outcome in Acute Myeloid Leukemia
Francesco Mannelli et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2014)
EVI1 overexpression is a poor prognostic factor in pediatric patients with mixed lineage leukemia-AF9 rearranged acute myeloid leukemia
Hidemasa Matsuo et al.
HAEMATOLOGICA (2014)
Prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia: a report from the Japanese Pediatric Leukemia/Lymphoma Study Group
H. Matsuo et al.
BLOOD CANCER JOURNAL (2014)
Appropriate dose reduction in induction therapy is essential for the treatment of infants with acute myeloid leukemia: a report from the Japanese Pediatric Leukemia/Lymphoma Study Group
Daisuke Tomizawa et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2013)
Dynamic Chemotherapy-Induced Upregulation of CXCR4 Expression: A Mechanism of Therapeutic Resistance in Pediatric AML
Edward Allan R. Sison et al.
MOLECULAR CANCER RESEARCH (2013)
A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia
Geoffrey L. Uy et al.
BLOOD (2012)
Identification of Hepatic Niche Harboring Human Acute Lymphoblastic Leukemic Cells via the SDF-1/CXCR4 Axis
Itaru Kato et al.
PLOS ONE (2011)
Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML
Zhihong Zeng et al.
BLOOD (2009)
Prognostic value of CXCR4 and FAK expression in acute myelogenous leukemia
Emmanuelle Tavernier-Tardy et al.
LEUKEMIA RESEARCH (2009)
Overexpression of CXCR4 predicts adverse overall and event-free survival in patients with unmutated FLT3 acute myeloid leukemia with normal karyotype
Sergej Konoplev et al.
CANCER (2007)
CXCR4 is a prognostic marker in acute myelogenous leukemia
Anke C. Spoo et al.
BLOOD (2007)
CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment
JA Burger et al.
BLOOD (2006)
Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist
HE Broxmeyer et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Interaction of bone marrow stromal cells with lymphoblasts and effects of predinsolone on cytokine expression
SL Wu et al.
LEUKEMIA RESEARCH (2005)
Relation between CXCR-4 expression, Flt3 mutations, and unfavorable prognosis of adult acute myeloid leukemia
EJC Rombouts et al.
BLOOD (2004)
Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins
M Konopleva et al.
LEUKEMIA (2002)
High expression of the chemokine receptor CXCR4 predicts extramedullary organ infiltration in childhood acute lymphoblastic leukaemia
R Crazzolara et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
Share Paper
